Ofatumumab markedly reduced disability progression independent of relapses versus teriflunomide . In another head-to-head trial, ponesimod was superior to teriflunomide with regard to annualised relapse rate (ARR), fatigue symptoms, MRI activity, brain atrophy, and no evidence of disease activity (NEDA) in the OPTIMUM study [2,3].
In a pooled analysis of the phase 3 ASCLEPIOS I/II trials in relapsing multiple sclerosis (RMS) patients, the effect of ofatumumab versus teriflunomide on confirmed disability progression independent of relapse activity (PIRA) was assessed. The risk of confirmed disability progression at 3/6 months (3mCDP/6mCDP) was evaluated in 3 subsets of patients:
A: without confirmed relapses during the study;
B: without confirmed relapses duri...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« High NEDA rates after 2 years of ocrelizumab Next Article
Switching from natalizumab to moderate- versus high-efficacy DMT »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.